Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATP Infusion in Moderate to Severe Alzheimer's Disease
NCT02279511Phase 2Completed
- Sponsor
- Grifols
- Start
- Dec 2014
- Primary completion
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adenosine 5'-triphosphate in Alzheimer's disease (AD) (4 arms), sponsored by Grifols. Primary endpoints: Detection of brain metabolic changes after ATP infusion by spectroscopy techniques (H + MRS) and Changes in Cogstate results. Started Dec 2014; status: completed.
02
Drugs
adenosine 5'-triphosphate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02279511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279511.